001     131531
005     20240228145605.0
024 7 _ |a 10.1148/radiol.2017162351
|2 doi
024 7 _ |a pmid:28628422
|2 pmid
024 7 _ |a 0033-8419
|2 ISSN
024 7 _ |a 1527-1315
|2 ISSN
024 7 _ |a altmetric:21194580
|2 altmetric
037 _ _ |a DKFZ-2017-06195
041 _ _ |a eng
082 _ _ |a 610
100 1 _ |a Paech, Daniel
|0 P:(DE-He78)c6e31fb8f19e185e254174554a0cccfc
|b 0
|e First author
245 _ _ |a T1ρ-weighted Dynamic Glucose-enhanced MR Imaging in the Human Brain.
260 _ _ |a Oak Brook, Ill.
|c 2017
|b Soc.
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1525856168_14346
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Purpose To evaluate the ability to detect intracerebral regions of increased glucose concentration at T1ρ-weighted dynamic glucose-enhanced (DGE) magnetic resonance (MR) imaging at 7.0 T. Materials and Methods This prospective study was approved by the institutional review board. Nine patients with newly diagnosed glioblastoma and four healthy volunteers were included in this study from October 2015 to July 2016. Adiabatically prepared chemical exchange-sensitive spin-lock imaging was performed with a 7.0-T whole-body unit with a temporal resolution of approximately 7 seconds, yielding the time-resolved DGE contrast. T1ρ-weighted DGE MR imaging was performed with injection of 100 mL of 20% d-glucose via the cubital vein. Glucose enhancement, given by the relative signal intensity change at T1ρ-weighted MR imaging (DGEρ), was quantitatively investigated in brain gray matter versus white matter of healthy volunteers and in tumor tissue versus normal-appearing white matter of patients with glioblastoma. The median signal intensities of the assessed brain regions were compared by using the Wilcoxon rank-sum test. Results In healthy volunteers, the median signal intensity in basal ganglia gray matter (DGEρ = 4.59%) was significantly increased compared with that in white matter tissue (DGEρ = 0.65%) (P = .028). In patients, the median signal intensity in the glucose-enhanced tumor region as displayed on T1ρ-weighted DGE images (DGEρ = 2.02%) was significantly higher than that in contralateral normal-appearing white matter (DGEρ = 0.08%) (P < .0001). Conclusion T1ρ-weighted DGE MR imaging in healthy volunteers and patients with newly diagnosed, untreated glioblastoma enabled visualization of brain glucose physiology and pathophysiologically increased glucose uptake and may have the potential to provide information about glucose metabolism in tumor tissue. © RSNA, 2017 Online supplemental material is available for this article.
536 _ _ |a 315 - Imaging and radiooncology (POF3-315)
|0 G:(DE-HGF)POF3-315
|c POF3-315
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed,
650 _ 7 |a Contrast Media
|2 NLM Chemicals
650 _ 7 |a Glucose
|0 IY9XDZ35W2
|2 NLM Chemicals
700 1 _ |a Schuenke, Patrick
|0 P:(DE-HGF)0
|b 1
700 1 _ |a Koehler, Christina
|b 2
700 1 _ |a Windschuh, Johannes
|0 P:(DE-He78)98b696ed60c17f4ddd0da9fdc20a2492
|b 3
700 1 _ |a Mundiyanapurath, Sibu
|b 4
700 1 _ |a Bickelhaupt, Sebastian
|0 P:(DE-He78)d2d971750bce6217eb90fff9b01e61f9
|b 5
700 1 _ |a Bonekamp, David
|0 P:(DE-He78)ea098e4d78abeb63afaf8c25ec6d6d93
|b 6
700 1 _ |a Bäumer, Philipp
|0 P:(DE-He78)4a14b13a372ab8bf853e4b650a6bd98a
|b 7
700 1 _ |a Bachert, Peter
|0 P:(DE-He78)29b2f01310f7022916255ddba2750f9b
|b 8
700 1 _ |a Ladd, Mark
|0 P:(DE-He78)022611a2317e4de40fd912e0a72293a8
|b 9
700 1 _ |a Bendszus, Martin
|b 10
700 1 _ |a Wick, Wolfgang
|0 P:(DE-He78)92e9783ca7025f36ce14e12cd348d2ee
|b 11
700 1 _ |a Unterberg, Andreas
|b 12
700 1 _ |a Schlemmer, Heinz-Peter
|0 P:(DE-He78)3d04c8fee58c9ab71f62ff80d06b6fec
|b 13
700 1 _ |a Zaiss, Moritz
|0 P:(DE-He78)db923d831c5fe9b5e8fab7794dd45c44
|b 14
|u dkfz
700 1 _ |a Radbruch, Alexander
|0 P:(DE-He78)77588f5b9413339755a66e739d316c7d
|b 15
|e Last author
773 _ _ |a 10.1148/radiol.2017162351
|g Vol. 285, no. 3, p. 914 - 922
|0 PERI:(DE-600)2010588-5
|n 3
|p 914 - 922
|t Radiology
|v 285
|y 2017
|x 1527-1315
909 C O |o oai:inrepo02.dkfz.de:131531
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 0
|6 P:(DE-He78)c6e31fb8f19e185e254174554a0cccfc
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 1
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 3
|6 P:(DE-He78)98b696ed60c17f4ddd0da9fdc20a2492
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 5
|6 P:(DE-He78)d2d971750bce6217eb90fff9b01e61f9
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 6
|6 P:(DE-He78)ea098e4d78abeb63afaf8c25ec6d6d93
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 7
|6 P:(DE-He78)4a14b13a372ab8bf853e4b650a6bd98a
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 8
|6 P:(DE-He78)29b2f01310f7022916255ddba2750f9b
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 9
|6 P:(DE-He78)022611a2317e4de40fd912e0a72293a8
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 11
|6 P:(DE-He78)92e9783ca7025f36ce14e12cd348d2ee
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 13
|6 P:(DE-He78)3d04c8fee58c9ab71f62ff80d06b6fec
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 14
|6 P:(DE-He78)db923d831c5fe9b5e8fab7794dd45c44
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 15
|6 P:(DE-He78)77588f5b9413339755a66e739d316c7d
913 1 _ |a DE-HGF
|l Krebsforschung
|1 G:(DE-HGF)POF3-310
|0 G:(DE-HGF)POF3-315
|2 G:(DE-HGF)POF3-300
|v Imaging and radiooncology
|x 0
|4 G:(DE-HGF)POF
|3 G:(DE-HGF)POF3
|b Gesundheit
914 1 _ |y 2017
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b RADIOLOGY : 2015
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Thomson Reuters Master Journal List
915 _ _ |a WoS
|0 StatID:(DE-HGF)0110
|2 StatID
|b Science Citation Index
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b RADIOLOGY : 2015
920 1 _ |0 I:(DE-He78)E010-20160331
|k E010
|l Radiologie
|x 0
920 1 _ |0 I:(DE-He78)E020-20160331
|k E020
|l Medizinische Physik in der Radiologie
|x 1
920 1 _ |0 I:(DE-He78)G370-20160331
|k G370
|l KKE Neuroonkologie
|x 2
920 1 _ |0 I:(DE-He78)E012-20160331
|k E012
|l Neuroonkologische Bildgebung
|x 3
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)E010-20160331
980 _ _ |a I:(DE-He78)E020-20160331
980 _ _ |a I:(DE-He78)G370-20160331
980 _ _ |a I:(DE-He78)E012-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21